Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
H. Miles Prince(Peter MacCallum Cancer Centre), M. D’Incan(Centre Hospitalier Universitaire de Clermont-Ferrand), Brigitte Dréno(Nantes Université), Timothy M. Kuzel(Rush University), Vladmir Cláudio Cordeiro de Lima, Oliver Bechter(Universitair Ziekenhuis Leuven), M. Beylot‐Barry(Université de Bordeaux), Tatyana Feldman(Hackensack University Medical Center), Pascal Wolter(KU Leuven), William L. Trepicchio(Unknown), José Antônio Sanches(Universidade de São Paulo), Maria Corinna Palanca-Wessels(Unknown), Michael Weichenthal(Christian-Albrechts-Universität zu Kiel), Richard Klasa, Erin Zagadailov(AbbVie (United States)), Kerry Taylor(Cancer Council Queensland), Madeleine Duvic(Cancer Clinic), Pablo L. Ortiz‐Romero(Hospital Universitario 12 De Octubre), Jan Walewski(The Maria Sklodowska-Curie National Research Institute of Oncology), Pietro Quaglino(Department of Medical Sciences), M. Bagot(Inserm), Oleg E. Akilov(University of Pittsburgh Medical Center), Julia Scarisbrick(University Hospital of Zurich), Franz Trautinger, Stéphane Dalle(Hospices Civils de Lyon), Judith Trotman(The University of Sydney), Huimin Lin(Takeda (United States)), Constanze Jonak, Reinhard Dummer(University Hospital of Zurich), Sean Whittaker(Guy's Hospital), Sarah McCue Horwitz(New York University), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Yi Liu(Wenzhou Medical University), Wenwen Zhang(Takeda (United States)), Yinghui Wang(Beijing Tongren Hospital), Dominique Bron, David C. Fisher(Dana-Farber Cancer Institute), Youn H. Kim(Stanford University), Ian D. Lewis, Meredith Little(Takeda (United States)), David Joske(Dana-Farber Cancer Institute), Rudolf Stadler(University Hospitals of the Ruhr-University of Bochum), Dirk Huebner(Takeda (United States)), Larisa J. Geskin(Columbia University Irving Medical Center)
Cited by 580
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k